ReNeuron Group plc Director Share Purchase (7377P)
21 Octubre 2021 - 1:00AM
UK Regulatory
TIDMRENE
RNS Number : 7377P
ReNeuron Group plc
21 October 2021
ReNeuron Group plc
("ReNeuron" or the "Company")
Share Purchase by a Director
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, was informed that on the 20
October 2021, the following purchase of the Company's ordinary
shares of 1p each ("Ordinary Shares") was made by a director of the
Company:
Name Title Number of Total beneficial Percentage
Ordinary interest in of Company's
Shares purchased the Company's Total Voting
Ordinary Shares Rights
Senior Independent
Barbara Staehelin Non-Executive Director 43,000 43,000 0.08%
------------------------- ------------------ ----------------- --------------
ENDS
Contacts:
ReNeuron www.reneuron.com/investors
Olav Hellebø, Chief Executive Via Walbrook PR
Officer
Catherine Isted, Chief Financial Officer
Stifel Nicolaus Europe Limited (NOMAD
and Joint Broker)
Ben Maddison, Stewart Wallace +44 (0)20 7710 7600
Allenby Capital Limited (Joint Broker) +44 (0)20 3328 5656
James Reeve/George Payne (Corporate
Finance)
Stefano Aquilino (Sales & Corporate
Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7407
Paul McManus / Alice Woodings 804 654
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments, without the need for immunosuppressive
drugs. The Company's lead cell therapy candidate is in clinical
development for the blindness-causing disease, retinitis
pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential delivery system for drugs that treat
diseases of the brain. The Company also has the ability through its
conditionally immortalised induced pluripotent stem cell (iPSC)
platform to make any tissue cells of choice; in-house programmes
are focused on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
(Disclosure in relation to share options granted to Directors
and PDMRs)
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Barbara Staehelin
---------------------------- -------------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Senior Independent Non-Executive Director
---------------------------- -------------------------------------------
b) Initial notification Initial notification
/Amendment
---------------------------- -------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
---------------------------- -------------------------------------------
b) LEI 2138003TU12CQ5TZO137
---------------------------- -------------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
---------------------------- -------------------------------------------
b) Nature of the Acquisition of ordinary shares
transaction
---------------------------- -------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
115p 43,000
---------------------------- -------------------------------------------
d) Aggregated information GBP49,450
---------------------------- -------------------------------------------
e) Date of the transaction 20 October 2021
---------------------------- -------------------------------------------
f) Place of the transaction London Stock Exchange AIM Market
---------------------------- -------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHURVWRAAURUAA
(END) Dow Jones Newswires
October 21, 2021 02:00 ET (06:00 GMT)
Reneuron (LSE:RENE)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Reneuron (LSE:RENE)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
